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Abstract
Progress in identifying new therapies for multiple sclerosis (MS) can be accelerated by
using imaging biomarkers of disease progression or abatement in model systems. In this
study, we evaluate the ability to noninvasively image and quantitate disease pathology
using emerging “hot-spot” 19F MRI methods in an experimental autoimmune encephalomy-
elitis (EAE) rat, a model of MS. Rats with clinical symptoms of EAE were compared to con-
trol rats without EAE, as well as to EAE rats that received daily prophylactic treatments with
cyclophosphamide. Perfluorocarbon (PFC) nanoemulsion was injected intravenously,
which labels predominately monocytes and macrophages in situ. Analysis of the spin-den-
sity weighted 19F MRI data enabled quantification of the apparent macrophage burden in
the central nervous system and other tissues. The in vivoMRI results were confirmed by
extremely high-resolution 19F/1H magnetic resonance microscopy in excised tissue sam-
ples and histopathologic analyses. Additionally, 19F nuclear magnetic resonance spectros-
copy of intact tissue samples was used to assay the PFC biodistribution in EAE and control
rats. In vivo hot-spot 19F signals were detected predominantly in the EAE spinal cord, con-
sistent with the presence of inflammatory infiltrates. Surprising, prominent 19F hot-spots
were observed in bone-marrow cavities adjacent to spinal cord lesions; these were not
observed in control animals. Quantitative evaluation of cohorts receiving cyclophosphamide
treatment displayed significant reduction in 19F signal within the spinal cord and bone mar-
row of EAE rats. Overall, 19F MRI can be used to quantitatively monitored EAE disease bur-
den, discover unexpected sites of inflammatory activity, and may serve as a sensitive
biomarker for the discovery and preclinical assessment of novel MS therapeutic
interventions.
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Introduction
Multiple sclerosis (MS) is an autoimmune inflammatory and demyelinating disease of the cen-
tral nervous system (CNS) that affects millions of people worldwide. The progressive form of
MS results in severe neurologic disability due to an accumulation of physical and cognitive
impairments [1, 2]. Treatment of progressive MS is especially challenging because of the
chronicity of the disease process. The complex cascade of MS lesion development involves
blood-brain barrier (BBB) breakdown, infiltration of inflammatory cells, demyelination, axonal
damage, and microglial activation [3]. Experimental autoimmune encephalomyelitis (EAE), a
family of disease models with key immunopathological features mimicking MS, has been
widely used to evaluate potential therapies in their preclinical stage [4, 5]. Both MS and EAE
are T cell-mediated diseases, where perivascular and parenchymal infiltrates target myelin anti-
gens in the CNS. Infiltrating tissue macrophages have been reported as crucial effectors of EAE
disease activation and progression [6–9]. The role of macrophages in EAE includes phagocyto-
sis, antigen presentation, secretion of and response to proinflammatory cytokines, production
of nitric oxide (NO) and superoxide radicals, and impairment of BBB and oligodendrocyte
function [10].
Quantitative monitoring of inflammation in EAE could serve as a diagnostic for disease pro-
gression and aid in the development and evaluation of novel treatments. Traditional methods
for assaying inflammation, such as histological staining and flow cytometry, are laborious and
necessitate tissue destruction, thereby precluding longitudinal assessment. In vivo imaging
techniques can overcome this bottleneck by noninvasively and quantitatively assessing inflam-
mation repeatedly over time. MRI is the modality of choice to noninvasively examine disease
severity in MS patients and is often used with Gd-based contrast agents to elucidate active BBB
breaches. Preclinical and clinical MRI studies have utilized iron-oxide nanoparticle imaging
agents; following intravenous injection, these agents label tissue macrophages to generate
hypointense regions in T2-weighted images indicative of inflammatory infiltrates [11–16].
However, these infiltrates represented by T2-weighted signal loss are often indistinguishable
from intrinsic or disease pathogenesis contrast sources. Also, T2 signal loss is not linearly pro-
portional to the number of infiltrating cells, thereby confounding quantitative image analysis
[17].
Prior work has demonstrated in situmacrophage labeling and tracking methods using fluo-
rine-19 (19F) MRI [18–30], including early work in an EAE rat model [27]. In this approach,
perfluorocarbon (PFC) nanoemulsion is administered intravenously to a subject, and the
nanoemulsion droplets are taken up in situ by cells of the reticuloendothelial system (RES),
particularly circulating phagocytes in the blood such as monocytes, macrophages, neutrophils,
and DCs [31]. When labeled cells accumulate in sufficient amounts at sites of inflammation,
they become detectable by spin-density weighted 19F MRI. The 19F MRI detects the intracellu-
lar PFC tracer agent, thereby enabling “hot-spot” tracking of inflammatory cells with high
specificity and no background [32]. Macrophages are the dominant contribution to MRI-
apparent 19F hot-spots. In addition, one can take advantage of the direct, linear correlation
between 19F signal and macrophage cell number to quantitate the macrophage burden directly
from the in vivo images [19, 22].
In this study, we explore the use of PFC imaging probes and 19F MRI to quantitatively assay
the inflammatory burden in EAE rats, including diseased subjects treated prophylactically with
an anti-inflammatory agent. We quantify 19F signal and inflammatory burden in vivo in the
spinal column, with and without cyclophosphamide treatment. Additionally, 19F NMR analysis
of panels of excised, intact tissues and organs was also used to examine the overall PFC biodis-
tribution in the rat model. Our results suggest that in situ PFC macrophage labeling and MRI is
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Experiments were carried out at, and in accordance with the guidelines provided by the Carne-
gie Mellon University Institutional Animal Care and Use Committee (IACUC), which
approved this study (authorization number AS13-03), and the National Institute of Health
Guide for the Care and Use of Laboratory Animals. Anesthesia and euthanasia were by isoflur-
ane and CO2 gases, respectively.
The EAE rat model was generated using previously reported methods [22, 33]. For in vivo
MRI studies, three experimental groups were prepared. In Group 1, N = 5 adult female dark
agouti (DA) rats (Harlan, Indianapolis, IN), 11 weeks old, were inoculated (Day 0) with a single
subcutaneous injection at the tail base containing homogenizing DA rat spinal cord (100 mg/
rat) with 100 μl of incomplete Freund’s adjuvant (IFA; Difco, Detroit, MI) and 2 mg of Myco-
bacterium tuberculosis. After disease induction, rats in all groups were monitored daily for
body weight and clinical symptoms of EAE. Symptoms were scored according to the conven-
tion: 0 = normal; 1 = limp tail; 2 = paraparesis with a clumsy gait; 3 = hind-limb paralysis;
4 = hind- and forelimb paralysis; 5 = moribund. We note that no rats progressed to stage 4 or
5. In Group 2 (control), N = 5 rats were inoculated as above, with IFA and mycobacterium
tuberculosis, but without the spinal cord homogenate. In Group 3 (therapeutic), N = 5 rats
received the same EAE-inducing inoculation as Group 1, but also received intraperitoneal (i.p.)
cyclophosphamide (Baxter, Deerfield, IL) at 20 mg/kg body weight and 500 mg/25 ml every
five days starting from Day 0.
For ex vivo NMR and flow cytometry studies of tissue samples, additional groups were pre-
pared. Groups 4 and 5 were EAE (N = 4) and control (N = 5) rats, respectively, and were pre-
pared identically to Groups 1 and 2, except were used exclusively for NMR analysis of fixed
tissues.
In Groups 1 and 4, upon the first signs that an animal reached clinical stage 2 (typically Day
12–14), rats received a single intravenous (i.v.) injection (1 mL) of PFC nanoemulsion (VS-
1000H; Celsense, Inc., PA) via the tail vein. The nanoemulsion contains 30% (v/v) perfluoropo-
lyether with a mean droplet size of 145 nm. VS1000H has a T1/T2 of approximately 500/350
ms at 7 T. The PFC nanoemulsion was formulated for preclinical use only. The total amount of
fluorine administered was ~5.0×1021 atoms. In Groups 2, 3, and 5, rats were administered PFC
at Day 14, as disease progression was not present.
For flow cytometry analyses, we prepared Groups 6 and 7 (N = 2, each) of EAE and control
rats, respectively, where the PFC nanoemulsion was rendered fluorescent prior to injection to
aid in flow cytometry analysis. We performed a premix step of the PFC nanoemulsion with a
lipophilic dialkylcarbocyanine (DiI, V22885, Molecular Probes, Inc., Eugene, OR) fluorophore
[22, 34]. The fluorescent inoculant (PFC-DiI) was prepared by mixing 5 mL nanoemulsion
with a 2 μl/ml DiI stock solution prepared according to manufacturer's instructions. After incu-
bating the nanoemulsion with DiI for 20 minutes at room temperature under gentile agitation,
the DiI molecules became associated with the PFC nanoemulsion droplets. The PFC-DiI
nanoemulsion was then injected into Groups 6 and 7 as above.
In vivo 19F MRI
Two days after PFC injection, MRI scans were acquired in Groups 1–3. During MRI, animals
were anesthetized with 2% isoflurane in 67% O2 and 33% N2O, placed on a mechanical
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ventilator (Harvard Apparatus, Holloston, MA), and core temperature was maintained at 37°C
using a heated pad. 19F/1H MRI data were acquired using a 7 T Bruker BioSpec scanner (Biller-
ica, MA). A birdcage volume coil was used that could be tuned to either 19F or 1H. For each rat,
two parasagittal 19F spin density-weighted data sets using a 19F RARE (Rapid Acquisition with
Refocused Echoes) sequence were acquired sequentially to cover the entire spinal cord and
hindbrain, where the rat was repositioned between scans. The scan parameters were TR/
TE = 1,000/12 ms, RARE factor = 8, number of averages (NA) = 800, field of view (FOV) =
4.5 × 9.0 cm2, resolution = 0.7 × 1.4 × 2 mm3. To provide anatomical context to the 19F slices,
T2-weighted
1H images were acquired using a spin-echo sequence. The 1H imaging parameters
were TR/TE = 1,000/11 ms, NA = 4, and resolution = 0.23 × 0.23 × 2 mm3. A reference capil-
lary with diluted PFC nanoemulsion (5% v/v) in 1% agarose were placed above the animal’s
torso, with one near the lungs and the other by the animal’s kidney. The 19F/1H MRI images
were fused and analyzed using Voxel Tracker software (Celsense, Inc., Pittsburgh, PA). For dis-
play purposes, the 19F was rendered in pseudo-color (“hot-iron”) scale and a threshold mask of
SNR = 2.5 was then applied to the images, which removed 99.3% of all voxels containing only
noise. In slices, 19F regions of interest (ROIs) were manually outlined aided by anatomical
guidance from the high resolution 1H images. ROIs of the 19F reference capillary and back-
ground noise were also delineated. The in vivo 19F signal in ROIs was calculated using Voxel
Tracker, as previously reported [19]. The external 19F capillary was used as an absolute 19F ref-
erence, and quantitative analysis yielded the apparent number of fluorine atoms within ROIs.
For 19F image quantification, full-dynamic range data without thresholds were analyzed.
Ex vivo 19F MRI
After in vivoMRI experiments, animals were euthanized. The intact vertebrae and spinal cord
were excised and fixed in 4% paraformaldehyde (PFA) for 24 hours. Thoracic vertebrae 5–7
were imaged using an 11.7 T Bruker micro-imaging system with a 19F/1H volume coil. For 19F,
RARE parameters were TR/TE = 900/12 ms, RARE factor = 8, NA = 2,400, field of view (FOV)
= 13.6 × 13.6 × 10.2 cm3, and resolution = 0.2 × 0.2 × 0.4 mm3. For 1H, co-registered, high-res-
olution T2-weighted RARE images were acquired with TR/TE = 800/11 ms, RARE factor = 8,
NA = 36, and resolution = 0.05 × 0.05 × 0.1 mm3.
Ex vivo 19F nuclear magnetic resonance (NMR) of excised tissues
NMR analyses were used to assay 19F content in the fixed spinal cord segments and organs
from Groups 4 and 5. Two days after PFC injection, these were euthanized by transcardial per-
fusion with phosphate buffered saline (PBS) followed by 4% PFA. The vertebral columns, with
intact spinal cords, and brains were necropsied, as were other intact internal organs and tissues
(lymph nodes, spleen, kidney, thymus, heart, lung, liver, femur, brain, salivary glands). The spi-
nal cord, except the sacral region, was partitioned at intervertebral discs into 15 segments, with
each segment containing 1 to 3 vertebrae. The spinal cord was dissected and weighed, and the
vertebral bone and spinal nerves discarded. The intact brain stem and cerebellum was also dis-
sected from the excised brain and weighed. Intact tissues specimens were placed at the bottom
of 10 mm NMR tubes (Wilman-Labglass, Vineland, NJ). The samples had a flame-sealed 1
mm diameter glass capillary tube (Kimble Kontes, Vineland, NJ) containing 10 μL of 2% (v/v)
trifluoroacetic acid (TFA) placed inside the NMR tube next to the tissue sample; the total fluo-
rine content of the TFA reference (Fr) was 4.9 × 10
18 atoms. One-dimensional 19F NMR spectra
were acquired at 470 MHz using a Bruker spectrometer with a repetition time of 5 seconds and
16 averages. Two distinct peaks were observed at approximately -76 and -91.5 ppm for TFA
and PFC, respectively. The total fluorine content of a sample was calculated from the integral
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of the peaks for the PFC (Is) and TFA (Ir), as previously described in [22]. Afterwards, the fluo-
rine content was normalized to the sample weight (Ws), yielding an inflammation index (Iinf)
with units of 19F atoms/gram of tissue. The inflammation index is defined as:
Iinf ¼ IsFr=ðIrWsÞ ð1Þ
Histology
After ex vivoMRI, histology sections were prepared from the fixed vertebrae at thoracic levels
5–7 from Groups 1–2. Tissues were embedded in paraffin, cut into 6 μm-thick transverse sec-
tions, and stained with hematoxylin and eosin (H&E).
Flow cytometry
To confirm the cell populations labeled by PFC, bone marrow was extracted from the femur
and vertebral bodies of EAE and control rats that had received PFC-DiI (Groups 6 and 7,
respectively). Single cell suspensions were generated, and the cells were stained for expression
of CD45, CD11b/c and Ki67. The cells were analyzed on an LSR II (BD Biosciences, San Jose,
CA) flow cytometer. The results were analyzed using FlowJo software (FlowJo LLC, Ashland
OR).
Statistics
All measurements are presented as mean ± standard error of the mean (SEM). When compar-
ing two groups of animals, two-tailed T-tests with unequal variances were performed. Multiple
groups were compared using one way analysis of variance (ANOVA). P-values< 0.05 were
assigned statistical significance.
Results
We employ in situ PFC labeling and 19F MRI to image inflammation in an EAE model and can
quantitatively assess the effects of immunomodulatory treatments in vivo. Moreover, we
observe significant PFC uptake in vertebral bone marrow cavities adjacent to the spinal cord
EAE lesions. Fig 1a displays a typical parasagittal 19F/1H composite image in an EAE rat
(Group 1), with 19F rendered in hot-iron pseudocolor and 1H in grayscale (Fig 1b). Substantial
19F signals are observed predominately in the vertebral column (Fig 1a), compared to control
rat from Group 2 (Fig 1c). The liver also displays 19F signal, as the RES is the blood clearance
pathway of the PFC (Fig 1a and 1c). High-resolution ex vivo 19F/1H MRI images support the in
vivo findings; substantial PFC is observed in the dorsal and lateral aspects of the spinal cord in
EAE rats (Fig 1d and 1e). Additionally, marked 19F signal was detected in the bone marrow of
the vertebral bodies, laminae, and spinous processes adjacent to the white matter lesions (Fig
1d). Previously it has been shown that the 19F signal intensity following i.v. PFC infusion arises
predominately from the presence of labeled macrophages and correlates linearly with macro-
phage burden [19, 22]. Three-dimensional renderings of these high-resolution 19F/1H data in
movie format are provided online in Supporting Information (S1–S3 Movies).
We next sought to quantitate the amount of inflammation observed in EAE rats in vivo,
with and without prophylactic anti-inflammatory treatment. The total amount of 19F signal in
the EAE spinal cord and vertebral bone was quantified by normalization to the external refer-
ence capillary containing a known amount of 19F. In Group 1, we found that an average of 9.5
±4.0×1019 19F atoms were localized in the spinal cord, whereas 29.0 ±7.1×1019 19F atoms were
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localized in the vertebral bone marrow. In animals receiving prophylactic cyclophosphamide
treatment, the 19F signal in the spinal cord significantly decreased compared to the untreated
EAE spinal cords (Fig 2; 2.6±1.1×1019 atoms versus 9.5±4.0×1019 atoms, p< 0.05). This 19F
signal reduction indicates reduced inflammatory burden in the treated animals. Interestingly,
the vertebral 19F signal was also greatly suppressed in the treatment group when compared to
Fig 1. In vivo and ex vivo 19F/1H MRI of EAE rat shows 19F signal arising from the spinal cord and
adjacent vertebral bonemarrow, indicating accumulation of inflammatory phagocytes. (a) In vivo
19F/1H fused sagittal image of an EAE rat spine demonstrating a long segment of robust 19F signal in the
spinal cord and vertebrae. 19F signal is also appreciated in the RES inferiorly. A “hot iron” pseudocolor
calibration scale is displayed in the top right. (b) The 1H image component of the fused image shown in (a) is
shown for anatomic detail. (c) In vivo 19F/1H fused sagittal image of a control, wild-type rat, demonstrating no
significant 19F signal in the spine. 19F signal is again appreciated in the RES inferiorly. (d) Ex vivo 19F/1H
fused axial image at the level of thoracic vertebra 6 of an EAE rat demonstrates 19F signal indicated
inflammatory loci predominantly in the vertebral bone marrow and in the dorsal and lateral columns of the
white matter of the spinal cord. Labels are br = brain, sc = spinal cord, vb = vertebral body, lc = lateral column,
dh = dorsal horn. (e) The 1H image component of the fused image shown in (d) is shown for anatomic detail.
doi:10.1371/journal.pone.0140238.g001
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the untreated EAE group (Fig 2; 9.9±2.9×1019 atoms versus 29.0±7.1×1019 atoms, p< 0.05).
Our findings indicate that EAE disease progression induces recruitment of phagocytes to the
white matter of the spinal cord and adjacent bone marrow, and the number of recruited phago-
cytes decreases by approximately 66% after cyclophosphamide treatment (Fig 2).
We assayed the biodistribution of the PFC probe to identify possible ‘off-target’ sites of mac-
rophage accumulation outside of the spinal cord and vertebral column in the EAE model. To
identify potential inflammatory sites, we used high-resolution NMR instrumentation for 19F
detection of the remaining intact (fixed) organs and tissues. The ex vivo 19F NMR results are
consistent with the presence of pathologic inflammatory cell infiltrates in the spinal cord and
bone marrow in EAE rats (Fig 3). The cervical, thoracic, and lumbar spines all showed signifi-
cantly higher 19F content in EAE rats compared with wild-type rats (p< 0.05, Fig 3). The other
organs assayed displayed no significant increase in 19F content in EAE rats. As expected, both
EAE and control rats showed 19F in RES-associated tissues (e.g., liver, spleen, lymph nodes),
consistent with the expected clearance route of the PFC nanoemulsion (Fig 3). The average
total amount of 19F measured by NMR per animal was comparable between the EAE and con-
trol rats (4.7±3.0×1021 atoms versus 6.3±0.7×1021 atoms, respectively, p = NS) two days after
PFC administration.
Basic histopathologic analyses of rat spinal cord and vertebrae was used to confirm EAE
induction. Consistent with MRI results, histology of EAE spinal cords shows pathological
inflammatory cell infiltrates in the lateral and dorsal columns of the white matter using H&E
stain (Fig 4), which are absent in the control animals. In the exact same EAE model, prior work
by Ahrens et al. [22] used immunohistochemistry to confirm intracellular co-localization of
the PFC droplets within spinal cord CD68+ cells having macrophage morphology.
We also performed preliminary flow cytometry analysis to further identify the cells that
were infiltrating the bone marrow sites. In these experiments, EAE or control rats (Groups 6
and 7) were injected with PFC-DiI. Two days later, bone marrow from the femur and vertebral
Fig 2. In vivo quantification of inflammation load in the spinal cord and vertebral bonemarrow in EAE
rats. 19F signal in the spinal cord and vertebral bone marrow is significantly increased in EAE rats compared
to wild-type rats (black vs. grey bars; p < 0.05 indicated by *). 19F signal in the spinal cord and vertebral bone
marrow of EAE rats is significantly decreased by prophylactic treatment with cyclophosphamide (black vs.
white bars; p < 0.05 indicated by **). The apparent number of fluorine atoms was measured by integrating
the signal in ROIs and normalizing the results to the signal in a reference capillary containing a known
concentration of fluorine, as discussed in Methods section.
doi:10.1371/journal.pone.0140238.g002
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bodies was extracted and analyzed by flow cytometry. The majority of the PFC-DiI positive
cells also stained for CD11c/b demonstrating that these cells belong to the myeloid lineage (Fig
5). There was no change in the frequency of PFC-DiI positive myeloid cells in the femoral bone
marrow in EAE versus control EAE rats (Fig 5, top panels). However, there was a small
increase in PFC-DiI myeloid cells in the vertebral bone marrow of EAE rats (Fig 5, bottom
right panel), consistent with the MRI data. The increased accumulation of PFC-DiI positive
cells could have been caused by increased migration of myeloid cells to the vertebral bone mar-
row, or increased proliferation of resident myeloid cells. However, staining for Ki67 did not
show an increase in proliferating cells in the vertebral bone marrow (S1 Fig). Future work will
determine whether this cellular accumulation is caused by changes in the migration of myeloid
cells with additional markers to further delineate the profile of the PFC-DiI positive cells, in
addition to cytokine profiling.
Discussion
In this paper we show that PFC nanoemulsion agents and 19F detection can be used to quanti-
tatively assay the spinal cord inflammatory burden of EAE in vivo. Surprisingly, we observe
that the EAE rats display significant levels of inflammation in the vertebral bone marrow cavi-
ties in proximity to the spinal cord lesions, and that these levels are reduced following adminis-
tration of anti-inflammatory agents. Accumulation of myeloid cells in the vertebral bone
marrow in proximity to EAE lesions has not been reported, despite the fact that the disease has
been studied since the 1930’s. We speculate that the apparent 19F signal observed in the verte-
bral bone marrow may be caused by up-regulated recruitment and/or production of
Fig 3. Ex vivo 19F NMRmeasurements of organ and tissue biodistribution of the PFC nanoemulsion shows pathological inflammatory infiltrates
into the spinal cord of EAE rats. 19F signal is significantly higher in the spinal cords of EAE rats compared to wild-type rats. 19F signal is high in the liver and
spleen of both control and EAE rats because of normal clearance of PFC agent by the RES. (*) indicates p < 0.05 with respect to the control group.
ILN = inguinal lymph node, MLN = mesenteric lymph node, and SC = spinal cord. We note that the decrease in 19F in the ILN in EAE rates is not statistically
significant.
doi:10.1371/journal.pone.0140238.g003
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monocytes/macrophages due to increased cytokine and chemokine concentrations in the vicin-
ity of spinal cord EAE lesions. Previous studies have revealed the importance of infiltrating
macrophages in the pathogenesis of EAE [9]. These cells may infiltrate from the adjacent verte-
bral bone marrow, and the increased presence of PFC-positive macrophages in the vertebral
Fig 4. Histolopathologic analyses of spinal cord of EAE rats.H&E stain demonstrates cellular infiltrates
(*) in the lateral column of the white matter of the spinal cord of an EAE rat (a), without evidence of any
corresponding cellular infiltrate in the spinal cord of a control rat (b). The central canal of the spinal cord is
seen at the left of both images.
doi:10.1371/journal.pone.0140238.g004
Fig 5. Flow cytometry analysis of bonemarrow cells from the femur (top panels) and vertebra (bottom
panels). Bone marrow cells from control (left panels) or EAE (right panels) rats were examined for expression
of PFC-DiI and CD11c/b on gated CD45+ cells. Results shown are representative of two similar experiments.
doi:10.1371/journal.pone.0140238.g005
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bone marrow may be a marker of increased migration. Preliminary flow cytometry studies did
not demonstrate evidence of increased proliferation, as measured by Ki67 staining, in the verte-
bral bone marrow (S1 Fig).
We note that bone marrow is inherently difficult to analyze unambiguously using conven-
tional lH MRI and metal-ion-based contrast agents. Moreover, alternative molecular imaging
techniques, such as bioluminescence imaging [35, 36] and positron emission tomography
(PET) [37] have been used to detect EAE inflammation, but these techniques have limited spa-
tial resolution and are challenged to correctly delineate the precise anatomical location of
apparent signals within the spinal cord and vertebral column. Also, with PET it can be difficult
to differentiate hypermetabolic inflammatory infiltrates from adjacent hypometabolic paren-
chyma pathology [38].
19F MRI offers exceptional specificity because of the extremely low endogenous 19F content
of tissue, thereby resulting in negligible background signal from the host. Only the 19F-labeled
cells are detected as hot-spots, and a high 19F SNR is not necessary. Quantification of the 19F
signal is directly proportional to the number of fluorine atoms present in 19F spin-density
weighted MRI, thereby yielding a quantitative marker of inflammation severity. The detection
of PFC labeled cells is intrinsically different from 1HMRI contrast agents, where one detects
the presence of the contrast agent indirectly via its effect on the relaxation rates of surrounding
protons in mobile water. The PFC acts like a ‘tracer’ agent rather than a contrast agent since
19F MRI directly detects the 19F atoms associated with the labeled cells. The PFC agent used in
this study is not degradable in vivo by any known enzyme or by acidic pH [39]. The plasma
half-life of the PFC nanoemulsion formulation used is ~9.5 hours in rats [21], and it is cleared
via the RES system and exhaled through the lungs [39, 40]. Generally, MRI-detectable macro-
phages labeled with PFC persist in inflammatory lesions for extended periods of time; for
example, in a mouse model of inflammatory bowel disease with the same imaging agent [19],
macrophages were observed in lesions for at least 30 days after PFC administration. Following
systemic administration, PFC nanoemulsions are taken up preferentially by circulating macro-
phages/monocytes in the blood, but phagocytic engulfment of PFC nanoemulsions has also
been demonstrated in very small numbers of B lymphocytes, neutrophils, and dendritic cells
[20, 26]. Thus, although the 19F signal demonstrated in this study was most likely attributable
to circulating phagocytes which had homed to inflammatory loci, it is also possible that other
cells contributed to the observed 19F signal. In a previous study, we estimated the in situ label-
ing efficiency of the same PFC agent to be approximately 15–20% of all macrophages within
the animal [19]. Also, determining the exact PFC uptake per macrophage in situ is difficult,
unlike for ex vivo labeling experiments [32]. Fortunately, the number of 19F atoms detected is
known to linearly correlate to the number of macrophages and thus the inflammatory burden
in vivo [19, 22].
Overall, our findings show that in vivo 19F MRI detection of macrophage burden in the spi-
nal cord and vertebral bone marrow serves as a sensitive quantitative marker for EAE disease
burden and the evaluation of treatment strategies.
Supporting Information
S1 Fig. Bone marrow cells from control (left panels) or EAE (right panels) rats were exam-
ined for expression of Ki67 and CD11c/b on gated CD45+ cells. Results shown are represen-
tative of two similar experiments.
(TIFF)
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S1 Movie. 3D movie of EAE rat MRI. Videos demonstrating volume-rendering of 19F MRI
signal overlaid upon sagittal 1H-MRI of the thoracic spine.
(MP4)
S2 Movie. 3D movie of EAE rat MRI. Videos demonstrating volume-rendering of 19F MRI
signal overlaid upon sagittal 1H-MRI of the thoracic spine.
(MP4)
S3 Movie. 3D movie of EAE rat MRI. Videos demonstrating volume-rendering of 19F MRI
signal overlaid upon sagittal 1H-MRI of the thoracic spine.
(MP4)
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